NEW YORK CITY, NY / ACCESS Newswire / November 9, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate ("Cytokinetics" or the "Company") (NASDAQ:CYTK).â?¯â?¯ Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged […]
NEW YORK CITY, NY / ACCESS Newswire / November 9, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. ("Inspire" or the "Company") (NYSE:INSP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail
NEW YORK CITY, NY / ACCESS Newswire / November 9, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against WPP Plc ("WPP" or the "Company") (NYSE:WPP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged
NEW YORK CITY, NY / ACCESS Newswire / November 9, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Fluor Corporation ("Fluor" or the "Company") (NYSE:FLR) and certain officers.�� The class action, filed in the United States District Court for the Northern District of Texas, Dallas Division, and docketed under
NEW YORK CITY, NY / ACCESS Newswire / November 9, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Quanex Building Products Corporation ("Quanex" or the "Company") (NYSE:NX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail
NEW YORK, NY / ACCESS Newswire / November 9, 2025 / If you suffered a loss on your Synopsys, Inc. (NASDAQ:SNPS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/synopsys-inc-lawsuit-submission-form?prid=176345&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call
NEW YORK, NY / ACCESS Newswire / November 9, 2025 / If you suffered a loss on your Fly-E Group, Inc. (NASDAQ:FLYE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fly-e-group-inc-lawsuit-submission-form?prid=176344&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
NEW YORK, NY / ACCESS Newswire / November 9, 2025 / If you suffered a loss on your aTyr Pharma, Inc. (NASDAQ:ATYR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/atyr-pharma-inc-lawsuit-submission-form?prid=176343&wire=1&utm_campaign=5 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
(AUST:AVH.AX),(NASDAQ:RCEL), VALENCIA, Calif., Nov. 09, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, Interim Chief Executive Officer, and David O'Toole, Chief Financial Officer, on November 12,
AVITA Medical to Host Investor Webinar Briefing GlobeNewswire November 09, 2025 VALENCIA, Calif., Nov. 09, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, Interim Chief Executive